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Abstract
Background: Evidence regarding the different treatment options of status epilepticus (SE) in adults is scarce. Large
randomized trials cover only one treatment at early stage and suggest the superiority of benzodiazepines
over placebo, of intravenous lorazepam over intravenous diazepam or over intravenous phenytoin alone, and
of intramuscular midazolam over intravenous lorazepam. However, many patients will not be treated successfully with
the first treatment step. A large randomized trial covering the treatment of established status (ESETT) has just been
funded recently by the NIH and will not start before 2015, with expected results in 2018; a trial on the treatment of
refractory status with general anesthetics was terminated early due to insufficient recruitment. Therefore, a prospective
multicenter observational registry was set up; this may help in clinical decision-making until results from randomized
trials are available.
Methods/Design: SENSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to
document patient characteristics, treatment modalities and in-house outcome of consecutive adults admitted for SE
treatment in each of the participating centres and to identify predictors of outcome. Pre-treatment, treatment-related
and outcome variables are documented systematically. To allow for meaningful multivariate analysis in the patient
subgroups with refractory SE, a cohort size of 1000 patients is targeted.
Discussion: The results of the study will provide information about risks and benefits of specific treatment steps in
different patient groups with SE at different points of time. Thus, it will support clinical decision-making and, furthermore,
it will be helpful in the planning of treatment trials.
Trial registration: DRKS00000725
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Background
Status epilepticus (SE) is a frequent neurological emer-
gency. There is yet no commonly accepted definition
regarding duration and features that distinguish an SE
from a ‘normal’ epileptic seizure. The International League
Against Epilepsy (ILAE) classification for seizures [1]
(Commission on Classification and Terminology of the
International League Against Epilepsy 1981) defines SE as
a seizure that persists ‘for a sufficient length of time or is
repeated frequently enough that recovery between attacks
does not occur’. Several authors operationalize the term
‘sufficient length of time’ as 30 min [2]. However, almost
all generalized tonic-clonic seizures last less than 5 min,
and most focal (complex partial or simple partial) seizures
last less than 10 min [3, 4]. In addition, there is evidence
suggesting that the magnitude of neuronal damage is
correlated to SE duration [5]. Therefore, recent studies
have adopted a much shorter time of duration such as ten
[6] or even 5 min [7, 8] as critical point of intervention.
And a new proposal for definition of SE suggests 5 min
for convulsive activity and 10 min for non-convulsive
(focal) activity as SE [9].
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There are several different classification schemes of
SE. Some of them focus on clinical semiology [1, 10] or
just distinguish between ‘convulsive’ and ‘non-convulsive’,
whereas others classify according to time latency and/or
response to treatment [11, 12]. Currently, the distinction
between ‘initial SE’ for the first 5–10 min and/or before
the first treatment step, ‘established SE’ for the following
minutes up to a total duration of about one hour during
which the second-line treatment is usually given, ‘refractory
SE’ for SE that does not respond to first- and second-line
therapy, and ‘super-refractory SE’ for SE recurrence after a
course of deep analgo-sedation are preferred [12] when
describing and discussing SE treatment. These terms will
also be used here.
Evidence for efficacy and safety of different treatment
options of SE is scarce. There are two large randomized
controlled trials assessing the effect of benzodiazepines
for the initial treatment in out-of-hospital situations [7, 8].
These showed the superiority of lorazepam over diazepam
and placebo [7], and the equivalence of immediate intra-
muscular application of midazolam over intravenous ap-
plication of lorazepam [8]. Another trial found superiority
of lorazepam over diazepam [13].
One large multicenter trial addressed the initial in-
patient treatment of SE [6], where lorazepam was superior
to phenytoin alone, while differences between the other
treatment arms (phenobarbital, diazepam/phenytoin,
lorazepam) were not significant. In this trial, almost
half of the patient had received some form of drug
treatment before inclusion into the study. Thus, this
study covers treatment of initial as well as established
SE. In summary, only four large class I – studies are
available for treatment of SE in adults, and only the
first treatment step was covered sufficiently to allow
sound treatment recommendations. In addition there
are some smaller randomized controlled trials com-
paring phenytoin with valproate [14, 15], lorazepam
with levetiracetam [16] or other combinations of different
substances. A multicenter randomized trial assessing the
effectiveness of barbiturates and propofol in refractory SE
had to be interrupted due to insufficient recruitment [17].
In general, these studies are mostly small, monocentric,
uncontrolled, have serious methodological flaws, or a
combination of these factors applies. Therefore, national
and international treatment guidelines for established,
refractory and super-refractory SE are based on insuffi-
cient evidence, in some instances only on some small
retrospective case series [12, 18].
There are several problems that have yet precluded
the initiation of a large Class-I trial for treatment of
established or refractory SE. Most of them are inherent
to studies performed in emergency situations: First,
owing to the lack of evidence, it is difficult to assess
equipoise of different treatment options. Second, while a
blinding (preferably of both the patient and the investi-
gator) to the different treatment options remains the
gold standard because biases can be avoided, treatment
options for established or refractory SE include various
intravenous anticonvulsants with very different infusion
modalities, side effects, and application precautions. To
maintain blinding, these differences have to be taken
into account and require considerable efforts regarding
packaging, shipping and storage. In addition, it may be
difficult if not impossible to establish a common infusion
speed or other treatment modalities, without giving ad-
vantage or disadvantage to one of the treatment arms
that might distort the results and render transfer of the
results into clinical everyday practice impossible. For ex-
ample, one of the disadvantages of phenytoin is the
limitation of infusion speed due to the potentially related
adverse effects, such as hypotension or cardiac arrhythmia,
while, if used with equal infusion speed to phenytoin,
valproate and levetiracetam might loose their poten-
tial advantage.
Informed consent (IC) causes other problems. In the
United States, there is an exemption for emergency care
research if the situation under study is emergent and po-
tentially life-threatening. This exemption could be essen-
tial for effective research in emergencies with impaired
awareness, in which to obtain the valid IC of the patient
might be impossible and there is usually no time to con-
tact a proxy. However, in other countries this exemption
may not be possible: In Germany, for example, informed
consent can be postponed but not entirely waived in
such cases.
In fact, the requirement to obtain IC may be one of
the main reasons of difficulties in patient recruitment in
studies of established and refractory SE. Other reasons
include reservations of the treating team against drug
studies, lack of resources to adequately perform inclu-
sion assessment, lack of incentives for the institution to
support such a trial, availability of drugs, treatment
habits of the doctors in an almost evidence free zone, or
a combination of any of these factors.
Another aspect increasingly gaining relevance is the
potential delay of drug application after the diagnosis of
SE. Duration of delayed initiation of treatment after
diagnosis of SE has been recently linked with dismal out-
come as this factor could contribute partly to rendering
status epilepticus “refractory” [19–21]. It would be inter-
esting to see the results, across several medical centers,
regarding the timing of treatment with respect to the
onset of status.
Finally, the planning, execution and evaluation of a
large drug trial involving institutions in several countries
with several hundreds of participants is demanding and
requires considerable financial and logistic resources. A
sufficiently powered trial that is able to detect an effect
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size of 15 % on the base of a success rate of 50 % for the
worst treatment option needs almost 300 patients per
treatment arm [22, 23]. If the recruitment phase is sup-
posed to remain below 3–4 years, more than 50 study
sites will be required to obtain an accrual rate of 10–15
patients per month [22]. The costs of a pragmatic open-
label design of such a trial in Europe were estimated to
be at least 5 million Euro [23]. A comparable double-
blinded trial might easily require the double to threefold
amount of money. Drug companies hesitate to fund a
large SE trial under the concern of implications of high
serious adverse events and mortality rates, and also of
the fact, that the market for intravenous anticonvulsants
is rather small. In Europe, no funding agency was pre-
pared to support a large drug trial. The NIH recently
granted a trial comparing IV levetiracetam, IV valproate
and IV phenytoin/fosphenytoin in treatment of estab-
lished SE (ESETT) utilizing an adaptive trial design [22].
Even if ESETT is to start in 2015, results cannot be
expected before 2018 or even later. At that time, new sub-
stances or treatment strategies might have been discovered
that will not be included into the study in question.
To bridge the gap between small series and the necessary
large randomized trial, an informal working group of ex-
perts in status epilepticus from German-speaking countries
(Germany, Austria, Switzerland) developed a prospective
multicenter registry for patients treated for SE.
Methods/design
Study design
SENSE is a prospective, multicenter, non-randomized,
observational registry study of consecutive cases. We
aimed to include university hospitals as well as non-
university hospitals to enhance generalizability of the
findings. Nine high-volume medical centres in Germany,
Austria and Switzerland with experience in SE-treatment
were recruited: a) Germany: Epilepsy Centre Hessen/
University of Marburg (F. Rosenow), University Hospital
Kiel (N. Lang), Klinikum Osnabrück (C. Kellinghaus),
Krankenhaus Barmherzige Brüder, Regensburg (C. Tilz);
b) Austria: Christian-Doppler-Klinik Universitätsklini-
kum der Paracelsus Medizinischen Universität Salzburg,
(E. Trinka), Krankenhaus Barmherzige Brüder, Linz
(C. Tilz), University Hospital, Innsbruck (I. Unterberger);
c) Switzerland: University Hospitals Basel (S. Rüegg),
University Hospital Lausanne (A.O. Rossetti). We aimed
to include university hospitals as well as non-university
hospitals to enhance generalizability of the findings.
Personnel collecting data from the patient charts and
entering data into the database were board certified neurol-
ogists, or neurology residents, or medical students in their
final year, or study nurses, who were specifically instructed
prior to data collection and personally supervised by one
of the authors during the data collection and entry.
Patients were treated in highly equipped emergency de-
partments or intensive care units with electronical data
entry and managing; thus, type, dosages and time points
of drug administration could be easily ascertained. The
increasing use of continuous Video-EEG monitoring also
allowed for exact and reliable determination of cessation of
NCSE, and in some cases also of NCSE onset.
Ethical approval and funding
The local ethics committee of each participating center
approved the final study protocol. The following ethics
committees reviewed and approved the study: University
Hospital of Marburg (Lead opinion for the German
Institutions), University Hospital of Kiel, Chamber of
Physicians Niedersachsen (for Osnabrück), Chamber of
Physicians Bavaria (for Regensburg), Paracelsus University
of Salzburg, Krankenhaus Barmherzige Brüder Linz,
University Hospital of Innsbruck, University Hospital of
Basel and University Hospital of Lausanne. Informed con-
sent was waived owing to the purely observational charac-
ter and complete anonymisation of the patients by all
ethic committees except one (Innsbruck), for which IC
was obtained for all patients from this centre. The study
was registered at the German registry for clinical studies
(DRKS) fulfilling the WHO-standards (DRKS00000725).
The study was not funded by any governmental, research
or commercial entity. Resources were drawn from non-
specific research funds of each institution.
Objectives
The main objective of the study is to document patient
characteristics, treatment modalities and in-house out-
come of adults treated for SE, and identify predictors of
outcome. The data collected in this study could also
identify gaps and opportunities for the management of
this medical emergency. Lacking adequate prospective
controlled trials, this will help both decision-making in
clinical practice and designing future clinical trials.
Particularly, following questions will be addressed: 1)
which factors determine successful SE treatment at each
treatment step? 2) what are the complications associated
with each substance and treatment modality? 3) which
factors determine global outcome at the time of hospital
discharge? (4) what is the relative prevalence of the
semiological subgroups of SE? 5) is there a significant
difference regarding SE treatment according to countries
or institutions?
Study population
All consecutive adult patients who are diagnosed with
SE at admission or at any point of the in-patient treat-
ment could be entered into the registry. SE is defined as
a) seizures lasting >5 min, or b) recurrent seizures with-
out regaining recovery of awareness over >5 min. or c)
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in comatose patients we applied the following EEG cri-
teria [24] for non convulsive SE (NCSE): (A) Epilepti-
form discharges (EDs) > 2.5 Hz, or (B) EDs ≤ 2.5 Hz or
rhythmic delta/theta activity (>0.5 Hz) AND one of the
following: (i) EEG and clinical improvement after IV
AED*, or (ii) subtle clinical ictal phenomena, or (iii)
typical spatiotemporal evolution of the EEG pattern.
Definition of inclusion and exclusion criteria
There is no commonly accepted time criterion for inclu-
sion in SE trials. However, the recent large trials focusing
on emergency first line therapy used seizure duration of
5 min or more as entry variable for convulsive SE [7, 8].
To increase comparability between our data and these
studies, we chose the same operational definition. Other
inclusion criteria were not defined.
Status-epilepticus-like EEG and clinical phenomena in
hypoxic brain injury are considered pathophysiologically
distinct from status epilepticus proper, and carry a very
specific and generally poor prognosis [25]. Therefore, we
excluded patients with status epilepticus-like encephal-
opathies after hypoxic brain injury. No other exclusion
criteria were applied besides age (<16 years).
Clinical data
The following variables were considered as crucial for an
observational registry:
– demographics: age at admission, gender
– health variables at time of SE onset: modified
Rankin scale, relevant known health problems
(comorbidities), history of previous seizures,
anticonvulsant treatment
– SE-related variables: Date and time of onset,
semiology (worst seizure type), consciousness
before treatment, etiology, EEG during SE (if
applicable). These data will allow calculating the
Status Epilepticus Severity Score (STESS, [26])
– Treatment-related variables: date and time of first
treatment, treatment before admission to hospital,
date and time of the first administration of any
anticonvulsant substance used, bolus dose, bolus
mode of administration, bolus infusion speed (if
applicable), maximum daily dose and mode of
administration, date and time of last dose applied,
reason for discarding the substance, intubation
date and time (if applicable), reason for intubation
(airway protection vs. intentional coma induction
for SE treatment), maximum serum levels of the
substances in use (if applicable), adverse event
documentation.
– outcome-related variables: date and time of
SE cessation (if applicable), date and time of
EEG-documentation of SE cessation (if applicable),
day of discharge from hospital, modified Rankin
scale at discharge, anticonvulsant medication at
discharge (if applicable).
The modified Rankin-scale – a global outcome meas-
ure of morbidity and impairment - was chosen because
of its easy applicability in a large variety of clinical sce-
narios with neurological diseases.
Management protocol
No common management protocol will be imposed on
the participating centres. However, most institutions
have established an in-house protocol that is closely re-
lated to the national diagnosis and treatment guidelines
published by the neurological societies of Germany,
Austria and Switzerland [27].
In general, diagnosis of SE and related conditions is
made using clinical examination, EEG or both. In most
cases, emergency cranial imaging with CT or MRI as well
as routine emergency blood analysis, sometimes lumbar
puncture, is performed. Most frequently, the first treat-
ment step consists in application of a benzodiazepine. If
this is not successful, intravenous application of anticon-
vulsants such as (fos-)phenytoin, valproate, levetiracetam,
or lacosamide follow. As third step, another anticonvulsant
is added and/or therapeutic coma is initiated using propo-
fol, midazolam or barbiturates. All treatment decisions will
remain at the discretion of the attending physicians.
Data quality
Data are collected prospectively from the admission of the
patient to the discharge. Documentation has to be started
latestat the third day after treatment to guarantee the data
quality. Data collection is performed using a 4-page paper
CRF (case report file) version or an eCRF through a regis-
try website using a centre-specific login and password,
and fully anonymized. At the beginning, each investigator
has been trained in the usage of the CRF and eCRF.
Sample size and data analysis
According to single centre observational registries [28–30]
each treatment step carries a likelihood of between 40 and
60 % to represent the last treatment step before SE cessa-
tion. Thus, a cohort of approximately 1000 patients would
be needed to reach a group size of 200–300 patients in the
refractory group (i.e., resistant to first- and second-line
treatments). This group size would be needed to as-
sess approximately 20 possible predictors of outcome
with a two-sided significance level of 5 %, a power of
80 % and an anticipated effect size of 10 %.
Data analysis
Calculations will be conducted according to incident pa-
tients (especially for mortality, where each patient cannot
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count for several exposures), and episodes (for example,
regarding treatment impact, where several exposures of
the same patient are potentially informative). Interval-
scaled and ordinal-scaled data will be presented as
median/percentiles in addition to mean/standard devi-
ation because normal distribution and variance homogen-
eity cannot easily be assumed for most of the variables.
Categorical variables will be presented as frequency/
percentages. Differences between outcome categories will
be analyzed using non-parametric tests such as Mann–
Whitney-U-test or Kruskal-Wallis-Test. Categorical
variables will be tested using the Chi-square test or
Fisher’s exact test (2x2 tables), as needed. Multivari-
able approaches will assess significance of variables of
interest after multivariable analyses. P values of <0.05
will be considered as significant (two-sided testing).
Statistical analysis will be performed using the latest
version of SPSS (Chicago, Illinois)
Discussion
When a large randomised controlled trial is not feasible,
the second best option for evaluating SE treatment options
is a prospective registry with a sufficient number of cases
recruited from a sufficient number of institutions of differ-
ent types (academic tertiary care centers and community
hospitals). Ideally, a prospective registry should include
many different sites in different countries. However, the co-
ordination would require considerable effort, starting with
organization and costs of meetings. In addition, a larger
number of patients would be required to account for larger
inhomogeneity between centers and countries, thus requir-
ing larger resources for data acquisition and data analysis.
Our efforts for acquiring additional funding (e.g. from
drug companies or independent research organisations)
showed that besides some general research fund resources
from most of the centers, no further support would be
available. In addition, a purely observational design
avoids the ethical, legal and financial problems men-
tioned above while guaranteeing a reasonable degree
of comparability and validity of the data. We feel that
there is an urgent need for new data regarding the
treatment options for established and refractory SE.
Therefore, and for other reasons mentioned above, a
prospective registry seems to represent the only solution
to collect data in a meaningful time to bridge the latency
until the results of a randomized trial could be available
At the same time, data from this registry can serve as
a pilot database to generate and adapt hypotheses and
determinants such as dose per body weight and infusion
speed for any future trial.
To avoid the investigation of a restricted group of pa-
tients, we will include all adults with SE regardless of
age, etiology and comorbidity except for patients with
hypoxic brain damage. The individual factors influencing
treatment success and outcome, particularly the reasons
for failure and success of a substance in specific circum-
stances, are not well understood. Failure to include
certain patient groups might result in a significant loss
of generalizability. Owing to the minimum of exclusion
and inclusion criteria and the simplicity of the observa-
tional flow, the registry is easy to implement in Non-
University hospitals with limited staff and will most
likely result in a patient mix representative of clinical
practice. We will not include children because etiologies,
treatment options and outcomes are markedly different.
In our view, pediatric SE would need a data collection
and analysis of its own, as well as postanoxic SE.
The evaluation of a large, heterogeneous patient group
using standardized definitions and documentation will
hopefully help in clinical decision making in an area of
emergency medicine where data with higher level of
evidence are still lacking.
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